Orchestra BioMed Holdings, Inc. (OBIO)

NGM – Real Time Price. Currency in USD

4.06

+0.15 (3.84%)

At close: May 12, 2026, 4:00 PM EDT

4.15

+0.09 (2.22%)

After-hours: May 12, 2026, 7:04 PM EDT

06.05.2026

Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement

NEW HOPE, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced the receipt of a $15 million payment from Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) pursuant to the previously disclosed Revenue Participation Right Purchase and Sale Agreement (the “Royalty Purchase Agreement”). The payment completes a scheduled tranche under the agreement and reflects Ligand's continued strategic capital support of Orchestra BioMed's late-stage cardiovascular programs, AVIM Therapy and Virtue SAB, which are both being evaluated in ongoing randomized, controlled pivotal trials.

06.05.2026

Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement

Payment fulfills previously disclosed funding commitment of $20 million and supports planned completion of the BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) evaluating Atrioventricular Interval Modulation Therapy (“AVIM Therapy”) in patients with uncontrolled hypertension and an indication for a pacemaker as part of the strategic collaboration between Orchestra BioMed and Medtronic This payment, together with $15 million received from Ligand and announced separately, represents a total of $35 million in strategic capital received under previously disclosed agreements NEW HOPE, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced the receipt of a $20 million investment from Medtronic, plc.

30.04.2026

FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy

Atrioventricular Interval Modulation (“AVIM”) Therapy Food and Drug Administration (“FDA”) Breakthrough Device Designations span the broader population of patients with uncontrolled hypertension despite medication at increased cardiovascular risk and the specific pacemaker-indicated population being evaluated in the BACKBEAT Trial The addressable U.S. patient population for AVIM Therapy, based on the indications for use specified in its Breakthrough Device Designations, comprises over 7.7 million adults with hypertension despite medication Breakthrough Device Designation supports favorable reimbursement pathways, including potential eligibility for New Technology Add-on Payment (“NTAP”) and Transitional Pass-Through (“TPT”) payment, which can facilitate broader, more timely patient access and provider adoption NEW HOPE, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced that the FDA has granted a second Breakthrough Device Designation (“BDD”) for AVIM Therapy specific to patients with uncontrolled hypertension despite the use of anti-hypertensive medications, and an indication for a pacemaker.

23.04.2026

Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026

NEW HOPE, Pa., April 23, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced two AVIM Therapy presentations at the Heart Rhythm Society (HRS) 2026 Annual Meeting.

12.03.2026

Orchestra BioMed Holdings, Inc. (OBIO) Surpasses Q4 Earnings and Revenue Estimates

Orchestra BioMed Holdings, Inc. (OBIO) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of a loss of $0.38 per share. This compares to a loss of $0.43 per share a year ago.

12.03.2026

Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

NEW HOPE, Pa., March 12, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today reported its full year 2025 financial results and provided a fourth quarter business update.

03.03.2026

Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRT

NEW HOPE, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced two presentations that will be given at the Technology Heart Failure and Therapeutics (“THT”) and Cardiovascular Research Technologies (“CRT”) 2026 Meetings highlighting the potential for the Company's Atrioventricular Interval Modulation Therapy (“AVIM Therapy”) program in hypertensive heart disease and heart failure patients.

Videos

No Data

There is no data to display

Press releases

06.05.2026

Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement

06.05.2026

Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement

30.04.2026

FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy

12.03.2026

Orchestra BioMed Holdings, Inc. (OBIO)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Orchestra BioMed Holdings, Inc. (OBIO)

Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement

Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement

FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy

Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026

Orchestra BioMed Holdings, Inc. (OBIO) Surpasses Q4 Earnings and Revenue Estimates

Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRT

Videos

No Data

Press releases

Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement

Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement

FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy

Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement

Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement

FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy

Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026

Orchestra BioMed Holdings, Inc. (OBIO) Surpasses Q4 Earnings and Revenue Estimates

Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRT

Videos

No Data

Press releases

Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement

Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement

FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy

Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

Search stocks

Orchestra BioMed Holdings, Inc. (OBIO)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Orchestra BioMed Holdings, Inc. (OBIO)

Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement

Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement

FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy

Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026

Orchestra BioMed Holdings, Inc. (OBIO) Surpasses Q4 Earnings and Revenue Estimates

Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRT

Videos

No Data

Press releases

Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement

Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement

FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy

Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement

Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement

FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy

Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026

Orchestra BioMed Holdings, Inc. (OBIO) Surpasses Q4 Earnings and Revenue Estimates

Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRT

Videos

No Data

Press releases

Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement

Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement

FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy

Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update